AccuADC

**AccuADC** is the name used by Defence Therapeutics for its preclinical antibody-drug conjugate program built on the company's Accum platform, which is designed to enhance intracellular delivery by promoting endosomal escape. Public company materials identify at least **AccuADC-001** and **AccuADC-002** as oncology ADC candidates, with reported focus on breast and gastric cancers; AccuADC-001 has also been associated with breast cancer specifically in some materials. Available public information indicates these are investigational **antibody-drug conjugates** rather than a single fully characterized drug entity, and the exact antibody target, linker, and payload for the umbrella term **AccuADC** are not consistently disclosed in source materials. Mechanistically, the program appears intended to combine tumor-targeting antibodies with cytotoxic payloads while using the Accum technology to improve intracellular trafficking and potency.

Other names

Accum antibody-drug conjugate program